Allero Therapeutics: a biopharmaceutical company developing next generation immunotherapies for immune mediated diseases
Abnormal immune response can cause chronic and life threatening conditions. Current therapies are injection-based, do not reinstate tolerance, but instead treat symptoms or suppress immune system with potential side effects.
An ideal therapeutic would restore normal immune balance/tolerance, avoid global immune suppression and treat the cause of the disease,
Based on research by the founders and their collaborators the team has identified a novel specific immunotherapy approach based on antigen-specific tolerance induction. The approach defines a platform technology which is broadly applicable to a range of clinical indications with profound unmet medical need, e.g. autoimmune and allergic diseases.
We can share all startup information
only to registered users.
To activate your account please confirm your email address by clicking on the link we sent to your inbox.
Email not received?
Please check your spam folder or contact us at email@example.com